SCHEMBL5498074

SCHEMBL5498074

FC(F)(F)c1ccccc1-c1ccc2nc(NCCc3ccccn3)ncc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.46
LCK P06239 6/20 0.42
KDR P35968 6/20 0.42
MAPK14 Q16539 6/20 0.42
FGFR1 P11362 1/20 0.42
CYP1A2 P05177 6/20 0.41
CYP3A4 P08684 5/20 0.41
CYP2D6 P10635 5/20 0.41
TSHR P16473 5/20 0.41
CYP2C19 P33261 5/20 0.41
CLK4 Q9HAZ1 5/20 0.41
USP2 O75604 4/20 0.41
ALDH1A1 P00352 2/20 0.41
CYP2C9 P11712 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 1/20 0.41
HIF1A Q16665 1/20 0.41
TRPA1 O75762 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5488816 0.86 KDM4E (0.46) BACE1FGFR1CYP1A2ALDH1A1HSD17B10
SCHEMBL5490452 0.84 LCK (0.52) BACE1LCKKDRMAPK14FGFR1
SCHEMBL5494839 0.84 FGFR1 (0.52) BACE1FGFR1CYP1A2CYP3A4CYP2D6
SCHEMBL5489127 0.84 FGFR1 (0.44) FGFR1CYP1A2ALDH1A1HSD17B10MAPK8
SCHEMBL5490633 0.82 GBA1 (0.47) FGFR1CYP1A2CLK4ALDH1A1ALOX15
SCHEMBL5498349 0.82 FGFR1 (0.42) FGFR1CYP1A2MKNK1MAPK8
SCHEMBL5492004 0.82 NAMPT (0.48) FGFR1CYP1A2MAPK8
SCHEMBL5495502 0.82 MAPK8 (0.51) FGFR1CYP1A2ALDH1A1HSD17B10MAPK8
SCHEMBL5496788 0.82 MAPK8 (0.49) FGFR1CYP1A2ALDH1A1HSD17B10MAPK8
SCHEMBL5498312 0.82 PGK1 (0.50) FGFR1CYP1A2CYP3A4CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP claimed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 EP claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US claimed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 WO claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 BACE1 3036/4885LCK 106/4885KDR 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.